information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Wednesday, 27 August 2014

D29p03



CDS :   2106-2357, 252 bp,  : predicted 9.0 kD protein (83 Aa)
misc_feature: 2142-2294, 153 bp, SdiA-regulated; Region: SdiA-regulated; cl19046

By Snapgen software:


By Artemis software:


Aa sequence (83 Aa):


 

misc_feature Aa sequence:





Region: SdiA-regulated; cl19046





Statistics on the protein properties:



-No helix-turn-helix nucleic acid binding motifs
 
-No prediction of transmembrane segments in protein 


- No PEST motif as potential proteolytic cleavage site 

- N0 site of cleavage between a signal sequence and the "mature exported protein"



Virtual 2D-gel: